Alzinova AB (publ)

Stockholm Stock Exchange ALZ.ST

Alzinova AB (publ) Return on Equity (ROE) for the year ending December 31, 2023

Alzinova AB (publ) Return on Equity (ROE) is NA for the year ending December 31, 2023. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Stockholm Stock Exchange: ALZ.ST

Alzinova AB (publ)

CEO	Dr. Tord Labuda M.Sc., Ph.D.
IPO Date	Nov. 25, 2015
Location	Sweden
Headquarters	Pepparedsleden 1
Employees	5
Sector	Healthcare
Industries Biotechnology 3D Printing Pharmaceuticals Vaccines

Description

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.

Key trends

Past 5 years